Foghorn made a cameo appearance in Who Framed Roger Rabbit, in the final scene at Marvin Acme's factory with several other Looney Tunes characters. Both parts of the name suggest the association with "Senator Claghorn." Foghorn Leghorn made numerous appearances in Tiny Toons Adventures in numerous roles as Acme Loonervesity's Professor of Hound Teasing, Baseball Coach and an obnoxiously loud Librarian. At its most raucous, it sounds similar to that of another Blanc voice: Yosemite Sam (a strictly Friz Freleng character). A leghorn is a breed of chicken, and foghorn describes the character's loud, overbearing voice. Foghorn Leghorn cartoon pictures collection 4. Foghorn Leghorn cartoon images gallery 4. He starred in only one episode of the show, in which he was trying to fit in with a gang of cool roosters and employed the help of Tweety and his friends before Lola Bunny suggested to just be himself, which came in handy when Barnyard Dawg chased the cool roosters. A toddler version of Foghorn made appearances in short music videos of Baby Looney Tunes. The rooster adopted many of Claghorn's catch phrases, such as "That's a joke, I say, that's a joke, son." The references to Claghorn were obvious to much of the audience when the Foghorn Leghorn cartoons first premiered, but like many of the references in WB cartoons of the era, they have since become dated. In April, The company paused enrollment on its Phase 1 trial of FHD-609 in patients with synovial sarcoma and SMARCB1-deleted tumors after a patient had a severe heart-related safety event.Foghorn Leghorn (Picture 4). In May 2022, the FDA instituted a partial clinical hold on Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory AML and myelodysplastic syndrome, converted to a full clinical hold in August. Preliminary data on immune modulation markers in the tumor microenvironment also indicated the potential for combination treatment with checkpoint inhibitors.įoghorn intends to initiate a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients, with the first patient scheduled to receive the treatment.Įarlier this month, the FDA lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia (AML) and myelodysplastic syndrome. Circulating tumor DNA reductions supported the observed clinical activity. One patient demonstrated a durable partial response and remained on treatment for over 16 months, while nine patients achieved stable disease.Įight patients exhibited tumor reductions in target lesions. Out of the 73 patients, 47 had target lesions for evaluation. Grade 3 or higher treatment-related events were mainly anemia, asthenia, ALP increase, hypokalemia, muscular weakness, and rash. The most common treatment-related adverse events included dysgeusia, fatigue, AST increase, nausea/vomiting, dry mouth, and rash. The clinical data from the Phase 1 study supported the safety and tolerability of FHD-286. The Phase 1 dose-escalation study of FHD-286 in metastatic uveal melanoma included 73 patients who had received a median of two prior therapies across nine different cohorts. However, Foghorn does not intend to pursue FHD-286 to treat uveal melanoma. These findings further validate the safety and tolerability profile of FHD-286. Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |